Ex-GSK scientists grab $18M, neurosciences portfolio for startup

A pair of former GlaxoSmithKline ($GSK) scientists specializing in neurosciences has grabbed $18.4 million in venture backing to launch a startup biotech pursuing a pipeline of programs spun out of the pharma giant. Dr. Emiliangelo Ratti and Dr. Mike Trower gained the rights to a portfolio of clinical and preclinical neurokinin receptor antagonists divested from GSK for the newly coined NeRRe Therapeutics in London. In recent years GSK has cut back significantly on the neurosciences front, creating some opportunities for others to carry on the work. Novo and Advent Venture Partners are backing the upstart. Release

 

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.